ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Novartis invests in CAR-T production in China

by Jean-François Tremblay
October 7, 2018 | APPEARED IN VOLUME 96, ISSUE 40

Novartis will inject $40 million into Cellular Biomedicine Group (CBMG), a Chinese firm that will produce Novartis’s Kymriah CAR T-cell treatment for people with cancer in China. Although Kymriah has yet to be approved in China, Novartis expects the government will give the go-ahead because China is home to the world’s largest group of people with the types of cancers that Kymriah treats. As part of the deal between the two companies, CBMG will receive an increasing percentage of the drug’s sales in China as the market grows.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment